Literature DB >> 25728833

Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis.

Ricardo E Carrión1, Barbara A Cornblatt2, Danielle McLaughlin3, Jeremy Chang3, Andrea M Auther4, Ruth H Olsen3, Daniel C Javitt5.   

Abstract

BACKGROUND: There is a growing recognition that individuals at clinical high risk need intervention for functional impairments, along with emerging psychosis, as the majority of clinical high risk (CHR) individuals show persistent deficits in social and role functioning regardless of transition to psychosis. Recent studies have demonstrated reduced reading ability as a potential cause of functional disability in schizophrenia, related to underlying deficits in generation of mismatch negativity (MMN). The present study extends these findings to subjects at CHR.
METHODS: The sample consisted of 34 CHR individuals and 33 healthy comparison subjects (CNTLs) from the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital in New York. At baseline, reading measures were collected, along with MMN to pitch, duration, and intensity deviants, and measures of neurocognition, and social and role (academic/work) functioning.
RESULTS: CHR subjects showed impairments in reading ability, neurocognition, and MMN generation, relative to CNTLs. Lower-amplitude MMN responses were correlated with worse reading ability, slower processing speed, and poorer social and role functioning. However, when entered into a simultaneous regression, only reduced responses to deviance in sound duration and volume predicted poor social and role functioning, respectively.
CONCLUSIONS: Deficits in reading ability exist even prior to illness onset in schizophrenia and may represent a decline in performance from prior abilities. As in schizophrenia, deficits are related to impaired MMN generation, suggesting specific contributions of sensory-level impairment to neurocognitive processes related to social and role function.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high risk; Early intervention; Mismatch negativity; Reading; Social functioning

Mesh:

Year:  2015        PMID: 25728833      PMCID: PMC4469046          DOI: 10.1016/j.schres.2015.01.030

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  49 in total

1.  Support for an association between mismatch negativity and social functioning in schizophrenia.

Authors:  Yuki Kawakubo; Kiyoto Kasai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-04-05       Impact factor: 5.067

2.  Reading impairment and visual processing deficits in schizophrenia.

Authors:  Nadine Revheim; Pamela D Butler; Isaac Schechter; Maria Jalbrzikowski; Gail Silipo; Daniel C Javitt
Journal:  Schizophr Res       Date:  2006-08-04       Impact factor: 4.939

3.  Impaired mismatch negativity is associated with current functional status rather than genetic vulnerability to schizophrenia.

Authors:  Minah Kim; Sung Nyun Kim; Suji Lee; Min Soo Byun; Kyung Soon Shin; Hye Youn Park; Joon Hwan Jang; Jun Soo Kwon
Journal:  Psychiatry Res       Date:  2014-03-04       Impact factor: 3.222

4.  A new method for off-line removal of ocular artifact.

Authors:  G Gratton; M G Coles; E Donchin
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1983-04

5.  Differential relationships of mismatch negativity and visual p1 deficits to premorbid characteristics and functional outcome in schizophrenia.

Authors:  Tamara Friedman; Pejman Sehatpour; Elisa Dias; Megan Perrin; Daniel C Javitt
Journal:  Biol Psychiatry       Date:  2011-12-21       Impact factor: 13.382

6.  Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis.

Authors:  Ricardo E Carrión; Terry E Goldberg; Danielle McLaughlin; Andrea M Auther; Christoph U Correll; Barbara A Cornblatt
Journal:  Am J Psychiatry       Date:  2011-05-02       Impact factor: 18.112

7.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.

Authors:  Michael F Green
Journal:  J Clin Psychiatry       Date:  2006-10       Impact factor: 4.384

8.  The global costs of schizophrenia.

Authors:  Martin Knapp; Roshni Mangalore; Judit Simon
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

Review 9.  The burden of schizophrenia on caregivers: a review.

Authors:  A George Awad; Lakshmi N P Voruganti
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Reduced mismatch negativity predates the onset of psychosis.

Authors:  Madiha Shaikh; Lucia Valmaggia; Matthew R Broome; Anirban Dutt; Julia Lappin; Fern Day; James Woolley; Paul Tabraham; Muriel Walshe; Louise Johns; Paolo Fusar-Poli; Oliver Howes; Robin M Murray; Philip McGuire; Elvira Bramon
Journal:  Schizophr Res       Date:  2011-10-24       Impact factor: 4.939

View more
  12 in total

Review 1.  Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.

Authors:  Daniel C Javitt
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

2.  Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis.

Authors:  Danielle McLaughlin; Ricardo E Carrión; Andrea M Auther; Doreen M Olvet; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Robert K Heinssen; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Terry E Goldberg; Philip D Harvey; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2016-04-22       Impact factor: 9.306

3.  Neurophysiological, Oculomotor, and Computational Modeling of Impaired Reading Ability in Schizophrenia.

Authors:  Elisa C Dias; Heather Sheridan; Antígona Martínez; Pejman Sehatpour; Gail Silipo; Stephanie Rohrig; Ayelet Hochman; Pamela D Butler; Matthew J Hoptman; Nadine Revheim; Daniel C Javitt
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

Review 4.  Electroencephalography and Event-Related Potential Biomarkers in Individuals at Clinical High Risk for Psychosis.

Authors:  Holly K Hamilton; Alison K Boos; Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2020-04-14       Impact factor: 13.382

5.  Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.

Authors:  Migyung Lee; Andrea Balla; Henry Sershen; Pejman Sehatpour; Peter Lakatos; Daniel C Javitt
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

6.  Predicting Remission in Subjects at Clinical High Risk for Psychosis Using Mismatch Negativity.

Authors:  Minah Kim; Tak Hyung Lee; Youngwoo Bryan Yoon; Tae Young Lee; Jun Soo Kwon
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

7.  Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications.

Authors:  Antígona Martínez; Pablo A Gaspar; Steven A Hillyard; Søren K Andersen; Javier Lopez-Calderon; Cheryl M Corcoran; Daniel C Javitt
Journal:  Am J Psychiatry       Date:  2018-10-03       Impact factor: 18.112

Review 8.  Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Authors:  Daniel C Javitt; Robert A Sweet
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

9.  Neural mechanisms of mismatch negativity dysfunction in schizophrenia.

Authors:  M Lee; P Sehatpour; M J Hoptman; P Lakatos; E C Dias; J T Kantrowitz; A M Martinez; D C Javitt
Journal:  Mol Psychiatry       Date:  2017-02-07       Impact factor: 15.992

10.  Social functioning and brain imaging in individuals at clinical high-risk for psychosis: A systematic review.

Authors:  Paul D Metzak; Megan S Farris; Thea Placsko; Amy Braun; Dominique Bonneville; Kali Brummitt; Monica Chu; Jean Addington
Journal:  Schizophr Res       Date:  2021-06-11       Impact factor: 4.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.